ABCL AbCellera Biologics Inc.
$12.16▲ +0.66%
Healthcare
Other
Volume 217.7K
Avg Volume (10D) 3.71M
Key Metrics & Fundamentals
Market Cap
$3.94B
P/E Ratio
–
Div Yield
0.00%
52W Range
2.75 - 15.02
% vs 50 MA
-0.72%
% vs 200 MA
80.84%
RSI-14
48.7
MACD Histogram
-0.1800
Beta (1Y vs SPY)
2.54
Free Cash Flow
$23.79M
Gross Rev
$4.05M
Gross Profit
$4.05M
EBITDA
-$50.14M
COGS
–
Operating Exp
$62.97M
Operating Income
-$58.92M
EBIT
-$58.92M
Pretax Income
-$58.97M
Net Income
-$55.43M
EPS (Diluted)
-0.18
Price & Volume History
Loading chart…
Recent News
AbCellera to Present at Upcoming Investor Conferences in November 2026
Business Wire · Oct 22, 2026 4:05 PM ET
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Zacks · Oct 12, 2026 4:25 PM ET
AbCellera Biologics' ABCL635 Seen With Best-in-Class Potential in Menopause, UBS Says
MT Newswires · Oct 12, 2026 12:55 PM ET
UBS Initiates AbCellera Biologics at Buy With $18 Price Target
MT Newswires · Oct 12, 2026 7:35 AM ET
AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws Focus
Simply Wall St. · Oct 9, 2026 7:10 PM ET
AbCellera to Present Phase 1/2 ABCL635 Data at Menopause Society Meeting
MT Newswires · Oct 9, 2026 11:28 AM ET
What Could Go Wrong With Recursion Pharmaceuticals Stock?
Trefis · Oct 8, 2026 7:58 PM ET
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Business Wire · Oct 8, 2026 4:05 PM ET
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Business Wire · Oct 1, 2026 4:05 PM ET
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
CNW Group · Oct 1, 2026 12:11 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ABCL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.